

MOVING FORWARD IN HATCH-WAXMAN LITIGATION

Brinks conducts validity and infringement reviews in connection with Paragraph IV certifications for abbreviated new drug applications or 505(b)(2) applications, and represents clients in related Hatch-Waxman litigation and other litigation in this and related fields. A representative list of compounds that we have worked on is below.

GENERIC PRODUCT

BRANDED PRODUCT

GENERIC PRODUCT

BRANDED PRODUCT

Alcaftadine	Lastacaft®	Levocetirizine	Xyzal®
Aspirin/dipyridimole	Aggrenox®	Memantine	Namenda XR®
Besifloxacin	Besivance®	Methylphenidate osmotic release	Concerta®
Bimatoprost	Lumigan®	Methylphenidate transdermal patch	Daytrana®
Budesonide	Pulmicort Respules®	Montelukast sodium	Singulair®
Buprenorphine/naloxone	Suboxone® sublingual film	Omeprazole	Prilosec®
Bupropion	Wellbutrin® XL	Pantoprazole	Protonix®
Cabazitaxel	Jevtana®	Paroxetine mesylate	Brisdelle®
Caspofungin	Cancidas®	Pemetrexed	Alimta®
Celecoxib	Celebrex®	Polycarbophil/chitosan ophthalmic	DuraSite 2®
Choline fenofibric acid	Trilipix®	Pramipexole	Mirapex ER®
Cefdinir	Omnicef®	Pregabalin	Lyrica®
Clindamycin phosphate and benzoyl peroxide	Onexton® Gel	Repaglinide	Prandin®
Dextromethorphan/quinidine	Nuedexta®	Repaglinide/metformin	PrandiMet®
Diclofenac sodium	Pennsaid®	Ropivacaine hydrochloride monohydrate	Naropin®
Dorzolamide-timolol	Cosopt® PF	Rosuvastatin calcium	Crestor®
Doxercalciferol	Hectorol®	Saxagliptin	Onglyza®
Duloxetine	Cymbalta®	Saxagliptin/metformin extended release	Kombiglyze®
Enoxaparin sodium	Lovenox®	Sevelamer hydrochloride	Renagel®
Eptifibatide	Integrilin®	Teriflunomide	Aubagio®
Esomeprazole	Nexium®	Testosterone	AndroGel®
Festerodine	Toviaz®	Ticagrelor	Brilinta®
Febuxostat	Uloric®	Valganciclovir hydrochloride	Valcyte®
Galantamine hydrobromide	Razadyne® ER	Venlafaxine	Effexor®
Gemcitabine	Gemzar®	Zolpidem	Ambien®